Related coverage linked through entity extraction aliases.
May 06, 2026
St. Jude researchers linked specific childhood cancer therapies to DNA fingerprints in second neoplasms, potentially improving survivor surveillance and guiding safer treatments. Separately, the Global Platform for Access to Childhood Cancer Medicines has helped Nepal and Ghana build national cancer registries and implement national strategies.
Jul 25, 2026
St. Jude Children’s Research Hospital experts are creating evidence-informed consensus guidelines covering brain tumor diagnosis, pharmacogenomics, survivorship care, and rare blood disorders. Their work helps clinicians translate the latest data into improved diagnosis, treatment, and follow-up care globally.
May 15, 2026
Only 17.7% of pediatric anticancer drugs advance to phase 3 trials, and just 12% earn FDA approval within 10 years, compared to 38.7% for adult drugs. The pace of pediatric approvals has accelerated recently, but funding and market size constraints remain.
Apr 23, 2026
WHO in January 2024 launched its first list of priority childhood cancer drug formulations, naming six medicines that still lack optimal child-friendly versions. The agency says about 400,000 children and adolescents develop cancer each year and is working to expand access to safe, effective paediatric formulations.
Mar 21, 2026
New AI-powered platforms enable same-day cancer treatment decisions and streamline clinical trial matching. University of Utah's μPharma chip predicts drug responses in under four hours, while City of Hope's HopeLLM system matches patients to trials across its national network.
Mar 06, 2026
New research examines both the long-term biological aging effects of childhood cancer treatments and proposes alternative treatment sequencing strategies to prevent tumor resistance and improve cure rates.
